

P1 1013891

REC'D 05 JUN 2003

WIPO

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

May 29, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/373,136

FILING DATE: April 17, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/12139

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



M. Sias

M. SIAS
Certifying Officer

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

PROVISIONAL APPLICATION COVER SHEET

A/PROV

request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(b)(2).

Docket #: 4830-14

Type a plus sign (+) inside this box→

+

INVENTOR(S)/APPLICANT(S)

NAME (First, Middle, Last)

RESIDENCE (City and either State or Country)

Diego A. GIANOLIO

737 Sommerville Avenue, #1
Sommerville, MA 02143

Erika E. JOHNSTON

71 Fulkerson Street, #302
Cambridge, MA 02141

Robert J. MILLER

500 E Falls Blvd., #5131
Quincy, MA 02169

TITLE OF THE INVENTION (280 characters max)

Aziridine Compounds and Their Use in Medical Devices and Drug Delivery Systems

CORRESPONDENCE ADDRESS

Kent H. Cheng, Esq.
(212) 687-2770Cohen, Pontani, Lieberman & Pavane
551 Fifth Avenue, Suite 1210
New York, New York 10176

ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification Number of Pages []
☐ Drawing(s) Number of Sheets []
☐ Other (specify): _

METHOD OF PAYMENT (check one)

☒ A check is enclosed to cover the Provisional filing fees
☒ If no check is enclosed or the enclosed check is insufficient - The Commissioner is hereby authorized to charge the filing fees or credit any overpayment to Deposit Acct. No. 03-2412.
PROVISIONAL FILING FEE
AMOUNTS: \$160

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government

☒ No☐ Yes, the name of the U.S. Government agency and the Government contract number are: _☐ Small Entity Status is claimed

Respectfully submitted,

Dated: April 17, 2002

COHEN, PONTANI, LIEBERMAN & PAVANE
 551 Fifth Avenue, Suite 1210
 New York, New York 10176
 (212) 687-2770

By: Kent H. Cheng

Kent H. Cheng
 Reg. No. 33,849

PROVISIONAL APPLICATION FILING ONLY

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

AZIRIDINE COMPOUNDS AND THEIR USE IN MEDICAL DEVICES AND DRUG DELIVERY SYSTEMS

Diego A. Gianolio
Erika E. Johnston
Robert J. Miller

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention is directed to novel uses of and products from aziridine compounds. More particularly, this invention is directed to plasma-deposited aziridine compounds in the form of a film. The film can be used to prevent biofouling or to immobilize a therapeutic agent. Even more particularly, this invention is directed to the use of such films in time release pharmaceutical compositions.

2. Description of the Related Art

It is known how to synthesize a variety of aziridine compounds using different methodologies. The use of aziridine compounds as inhibitors of aluminum corrosion and as biomedical agents are also known.

For example, W. McCoull, et al. (*Synthesis 2000*, No. 10, 1347-1365) disclose a summary of the use of chiral aziridines in synthesis emphasizing the effect of various substituents on ring openings, rearrangements and the use of chiral ligands and auxiliaries.

Netherlands Patent Application 19,650,414 discloses aziridinyl compounds that are useful as inhibitors of aluminum corrosion by halogenated hydrocarbons.

French Patent Application 19,650,413 discloses aziridinyl compounds that are useful as inhibitors of aluminum decomposition by halogenated degreasing agents and as inhibitors of the growth of *Escherichia coli*.

SUMMARY OF THE INVENTION

It has now been found that aziridine compounds can be formed into films by plasma deposition on a wide variety of substrates. The films prevent biofouling, impart biocompatible or antithrombotic properties, and can immobilize therapeutic and pharmaceutical agents to provide a drug delivery system.

In general, the invention is directed to a process of producing a coated surface on a substrate by plasma depositing an aziridine compound onto the substrate to produce at least one aziridine coated surface on the substrate.

The substrate may be generally any compatible material, including polyethylene terephthalate, polycarbonate, polymethacrylate, silicone, polytetrafluoroethylene, polyurethanes, polybutadienes, epoxies, polystyrenes, polybutyrates, hydroxy apatites, ceramics, glass, and metals, such as stainless steel, nitinol, and titanium. The substrate is preferably cleaned by, for instance, etching with oxygen before the plasma deposition of the aziridine compound.

The aziridine compound may have at least one other functional group selected from the group consisting of alkyl, allyl, alkoxy, alkylene, aryl, ester, ether, ethylene glycol, oligoethylene glycol, and acryl.

Preferably, the aziridine compound has a molecular weight of 600 or less so as to have sufficient vapor pressure for use in plasma deposition. It is preferred that the aziridine compound form radical ions during plasma deposition to facilitate the formation of the aziridine film on to a substrate. In one embodiment of the present invention, the aziridine is

linked to an acryl group by a linker selected from the group consisting of alkyl, alkylene, alkylene oxide, alkyl diols, and combinations thereof. The linker may be polypropylene oxide, polyethylene glycol or a combination of both. One preferable aziridine compound for plasma deposition is 2-(1-aziridinyl) ethyl methacrylate.

5 The process of plasma deposition may further include the step of coating the
aziridine coated surface with a biopolymer, such as a protein, heparin complex,
polysaccharide, phosphonic acid, and nucleic acid. The polysaccharide may be, but is not
limited to, hyaluronan, alginate, or carboxymethyl cellulose. The protein may be, but is not
limited to, collagen, laminin or albumin. The nucleic acid may be, but is not limited to, DNA,
10 RNA or antisense material. Furthermore, blood compatibility may be also imparted by
exposing the aziridine surface to blood which in turn will result in the covalent deposition of
blood proteins onto the surface. Adherence of serum albumin would passivate the surface to
further thrombus formation through the binding and activation of fibrinogen.

15 The process of the present invention provides a device having a plasma
deposited film of an aziridine compound on at least a portion of its surface. The film is
capable of preventing biofouling, such as cell and platelet adhesion when the device is in
contact with blood, plasma or tissue. The film may also impart biocompatible or
antithrombotic properties to the device. If a pharmaceutical or therapeutic agent is
immobilized onto the film, the device may be used as a controlled release drug delivery
20 system.

The pharmaceutical or therapeutic agent includes, but is not limited to, anti-allergenics, anti-bacterials, anti-virals, anti-fungals, anti-inflammatories, antiplatelets, antithrombotics, anesthetics, anti-proliferatives, genetic materials and mixtures thereof. The genetic materials may be, but is not limited to, DNA, RNA and antisense material.

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219

BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows the rate of release of Tranilast in saline solution at pH 6.0 and 9.7 from PET samples coated with a plasma-deposited aziridine film. This rate of release is compared with the release of Tranilast from PET control samples that do not have the aziridine film.

DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

Single or multi-layer coatings are provided herein that are designed to impart thromboresistance and/or biocompatibility to a medical device or provide a drug delivery system.

The first coating of the present invention initially is a plasma-deposited film formed from a compound having an aziridine functional group. The compound may further have groups such as alkyl, allyl, alkoxy, alkylene, aryl, ester, ether, ethylene glycol, oligoethylene glycol, and acryl. The aziridine compound may contain more than one aziridine functional group. Useful aziridine compounds include, but are not limited to, diaziridines such as di[2-(1-aziridinyl)ethyl]adipate, pentaerythritol tris(3-aziridinopropionate), discussed in GB 2,151,244 and 2,151,246 of Balazs et al.; 1,3-bis(1-aziridinyl)-3-phenyl-1-propanol; 1,1'-(1,3-propanediyl)bis-2-aziridinecarbonitrile, discussed in German Patent DE 2163623; α , β -bis(1-aziridinyl) 2-furanpropanol; 1-[3-(1-aziridinyl)propionyl]-aziridine; 1,3-bis(1-aziridinyl)-2-propanol; 1,3-bis(2-methyl-1-aziridinyl)-2-propanol; (1-aziridinylpyruvoyl)-, 1-[(p-nitrophenyl)hydrazone] aziridine; 1,1'-(1,3-dioxo-1,3-propanediyl) bis-aziridine, and those

5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

diaziridines disclosed in Andersson et al., Tetrahedron 54(38), 11549 (1998); Tanner et al., Acta Chem. Scand. 50(4), 361 (1996); Olivier et al., J. Org. Chem. 60(15), 4884 (1995); Russian Patent SU 1723125 (bisaziridine alkanes); Kadorkina et al., Izv. Akad. Nauk SSSR, Ser. Khim. 4, 882 (1991); Manecke et al., Makromol. Chem. 175(6), 1833 (1974); Manecke et al. German Patent DE 1270287; Watanabe et al., Kogyo Kagaku Zasshi 72(6), 1349 (1969); and Hillers et al.; Bestian et al., German Patent DE 1243687.

The molecular weight of the aziridine compound must be low enough to allow for the vaporization of the compound during plasma deposition. Preferably, the molecular weight is not more than 600.

Coatings of the present invention may be applied to medical devices that are placed in the human body, or that remain outside the body. Coated medical devices that are placed in the human body may include stents, catheters, needles, prostheses, surgical assist devices, picc lines and other devices. Coated medical devices that remain outside the human body may include tubing for the transport of blood and vessels for the storage of blood, dialysis filters, oxygenation membranes, and blood filters. Substrates or medical devices on which the coatings described herein may be applied can include a wide variety of materials, including stainless steel, nitinol, tantalum, glass, ceramics, nickel, titanium, aluminum and other materials suitable for manufacture of a medical device.

The coatings disclosed herein may further include a film-forming agent for the aziridine coating. The film forming-agent could be added in a second layer. For example, the aziridine coating comprising aziridine functionality may be chemically linked to a biopolymer

as a second layer that provides anti-thrombogenicity or biocompatibility. The biopolymer may be selected from a group of proteins, heparin complexes, polysaccharides, phosphonic acids, and nucleic acids. Polysaccharides include, but are not limited to, hyaluronan, alginate, and carboxymethyl cellulose. Appropriate film-forming agents could also include cellulose esters, polydialkyl siloxanes, polyurethanes, acrylic polymers or elastomers, as well as biodegradable polymers such as polylactic acid (PLA), polyglycolic acid (PGA), copolymers of PLA and PGA, known as PLGA, poly(ϵ -caprolactone), and the like.

Various methods of making the second layer of the present invention are possible, and examples of such methods and certain resulting coatings are as follows. Such methods and coatings are disclosed by way of example, and are not intended to be limiting, as other examples may be readily envisioned by one of ordinary skill in the art. The following examples include methods of providing coatings of the present invention in a single layer having the aziridine compound, with and without the need for a second layer. In some instances, experimental results are provided showing sustained bioactivity for a particular coating.

The second layer can be applied in a wide variety of conventional ways, including painting, spraying, dipping, vapor deposition, epitaxial growth and other methods known to those of ordinary skill in the art.

Coatings, derived from the above-described methods, on coupons were tested in various ways. First, as a qualitative test, coupons coated with an aziridine first layer alone were dipped in rhodamine B solution and then were screened for the presence of a pink stain.

5
The presence of a pink stain indicates the presence of reaction between aziridine and rhodamine B in the sample being assayed. Additionally, the intensity of the color observed in this assay is proportional to the amount of aziridine in the sample. Therefore, a comparison of the intensities of the color produced in this assay in a set of samples allows an assignment of the relative amounts of aziridine comprised by the coatings of those samples.

Similarly, where a second layer is applied onto the aziridine first layer, the second layer may be determined by another stain. In the case where the second layer is hyaluronan, an Alcian blue stain may be used to detect the presence of the hyaluronan layer.

10
The second layer may also be derived from exposing the aziridine layer to blood which in turn affects the immobilization of serum blood proteins to the surface and renders the surface passive to platelet activation.

The invention and its various embodiments will become more apparent from the following examples, which further illustrate preferred embodiments thereof.

15 EXAMPLE I

SYNTHESIS OF 2-(1-AZIRIDINYL) ETHYL METHACRYLATE

20 Under a nitrogen atmosphere, 14.4 mL of aziridineethanol (0.18 mole) and 30 mL of anhydrous dimethylformamide were placed into a dry 500 mL flask. To this there was added 75.3 mL of triethylamine (0.54 mole) and the mixture was stirred on ice for 30 minutes. To this mixture there was added dropwise 22.3 mL methacrylic anhydride (0.15 mole) and this was then stirred at room temperature overnight. The contents of the flask were then poured

into a separatory funnel and the product was extracted with dichloromethane from sodium bicarbonate-saturated water twice and from brine once. The solvent was removed *in vacuo* and the desired product was purified by distillation and collected at 50 °C at 0.1 mm of Hg. 2-(1-Aziridiny) ethyl methacrylate, 7.0 g (0.045 mole) was obtained (30% yield) as a colorless oil

having the following analysis:

^1H NMR (400 MHz, CDCl_3); δ = 1.19(t, J=20Hz, 2H, CH), 1.79(t, J=20 Hz, 2H, CH), 1.96(s, 3H, CH), 2.50(t, J=5.6Hz, 2H, CH), 4.32(t, J=5.6Hz, 2H, CH), 5.58(s, 1H, H alkene), 6.14(s, 1H, H alkene)ppm.

^{13}C NMR (100 MHz, CDCl_3); δ = 18.5; 27.4; 59.9; 64.7; 125.9; 136.4; 167.6 ppm.

IR: (KBr) 2986.00; 1717.48; 1633.56; 1454.54; 1295.10; 1166.43; 937.06 cm^{-1} .

EXAMPLE II

PREPARATION OF AZIRIDINE FILMS

A. Deposition

A plasma reactor was used for depositing the films. The plasma reactor has a 4" diameter x 24" long cylindrical glass chamber with inlet and exit ports at either end for vapor flow and an additional port for measuring reactor pressure. Capacitance coupled electrodes formed by two 1" wide strips of brass were wrapped around the outside of the reactor and spaced 6" apart. The downstream electrode was electrically grounded. A radio frequency generator and impedance matching network were used to apply an oscillating potential of desired power (5-100 watts) and frequency (13.56 MHz) to the upstream electrode.

Flowmeters for inert gases and precursor vapors are located and connected upstream of the reactor.

5
10
15
In this capacitively coupled plasma reactor, aziridine films were plasma deposited onto polyethylene terephthalate (PET) sheets within the reactor. To do so, solvent sonicated samples of the films were placed in the reactor and etched with oxygen to activate their surfaces. The 2-(1-Aziridinyl) ethyl methacrylate compound of Example I was warmed to 33-36 °C, degassed and fed into the plasma reactor via a mass flow controller at a controlled rate of 20sccm (200 mtorr). A radio frequency was applied at 80w, 13.56 MHz for two minutes whereupon the deposition power was decreased to 30-35 watts for 5-8 minutes. A temperature of 33-36 °C for the 2-(1-Aziridinyl) ethyl methacrylate compound provided the mass flow controller with sufficient vapor to sustain a 20sccm flow rate for the duration of the deposition plus a 5-10 minute post-deposition aziridine vapor quench. Following the quench, argon was flowed across the samples for 10 minutes at a rate of 4sccm (100mtorr) and the samples were then left under an argon environment until they were removed from the reactor.

15 The thickness of the deposited aziridine film on the samples is most likely greater than 100 Å.

B. Aziridine Functionality

Several samples produced in Example IIA in 0.5 x 2.5 cm pieces and having an overall thickness of about 0.5 mm were soaked overnight in 0.1% rhodamine stain solution.

20 The rhodamine stain solution contained 0.03M succinic acid and 0.12M NaCl, and was pH adjusted to 4.10 with 5N NaOH. The soaked samples were then rinsed in deionized water and

dried. The color of the samples were then determined. An increased in the pink color that is exhibited by the samples correlates with an increased presence of functional aziridines on the surface of the samples. No pink color was observed in PET controls that do not have the plasma-deposited aziridine film.

C. Formation of Lipid Enriched Layer

Samples of the plasma-deposited aziridine film on PET from Example IIA were exposed for 3 hours to 10 ml of isopropyl alcohol (IPA) solution containing 0.278g tetradecyl phosphonic acid ($C_{14}PO_4$). The samples were then rinsed with IPA to remove any unbound $C_{14}PO_4$. Contact angles of the rinsed samples were measured with a Rame-Hart contact angle goniometer manufactured by Advanced Surface Technologies in Billerica, MA.

The contact angle of a first sample having an aziridine film exposed only to IPA is $69.7^\circ \pm 0.9^\circ$ ($n=3$, 1σ). The contact angle of a second sample having an aziridine film exposed to a IPA/ $C_{14}PO_4$ solution is $88.4^\circ \pm 0.8^\circ$ ($n=3$, 1σ). The increased contact angle of the second sample indicates that the hydrophobic chains of the tetradecyl phosphonic acid ($C_{14}PO_4$) were present on the sample surface.

X-ray Photoelectron Spectroscopy (XPS) analysis of the second sample indicated the incorporation of 2.8% phosphorus, an increase in carbon content and a decrease in nitrogen content in the outermost 100 Å of the surface. Consistent with the measurement of contact angle, the XPS analysis indicated that the alkyl phosphonic acid had been incorporated into the surface of the second sample.

EXAMPLE III**DRUG BINDING AND RELEASE**

5 Samples of the aziridine deposited film and samples of PET as controls were
soaked in 0.5M of Tranilast in 1-methyl-2-pyrrolidinone (NMP) solution for five days at room
10 temperature. It was anticipated that the carboxylic acid group of Tranilast would react with the
aziridine ring present in the plasma deposited film to form ester bonds. The presence of such
ester bonds was determined by measuring the Tranilast release at two pH levels since the
hydrolysis rate of ester bonds is slow in neutral solutions, but increases under either more
basic or more acidic conditions. Samples of the aziridine deposited film and PET controls
were soaked in 0.85% saline (at pH 6.0) and in saline plus 0.3mM HEPES buffer (at pH 9.7).
At intervals of 2, 4, 6 and 8 days, the samples were transferred to fresh saline solution of the
appropriate pH and the absorbance measured at 340nm to determine the concentration of
Tranilast in the solution.

15 It was found that the initial burst of Tranilast release was greater from the PET
controls than from the aziridine films. After the initial burst release from the PET samples, no
additional Tranilast release was detected. However, Tranilast continued to be released from
the aziridine film samples for 3-7 days. These findings indicate that the Tranilast release rate
was greater at pH 9.7 than at pH 6.0 and that the Tranilast was bound to the aziridine ring via
20 ester linkages. Figure 1 summarizes the observed release of the Tranilast from various
samples at pH 6.0 and 9.7.

EXAMPLE IV

HYALURONIC ACID BINDING

A set of plasma-deposited aziridine films on PET samples from Example IIA in 1 cm x 2.5 cm pieces were exposed to a 0.1w% of 1 MDa hyaluronic acid (HA) solution at room temperature. The HA solution was buffered at pH 4.11 with 0.03M succinate buffer. The samples were then soaked for 2 hours in phosphate buffer saline (PBS) at 37 °C to remove weakly bound HA, then stained for 10 seconds with 1% Alcian blue, and rinsed in deionized water.

The samples exposed to the Alcian blue stain developed a faint blue color, indicating the presence of a thin HA layer. A control sample of plasma-deposited aziridine film on PET that was not exposed to an HA solution failed to stain with Alcian blue indicating that the stain did not bind nonspecifically to the aziridine film. The blue color did not fade from the samples of the Alcian blue stained HA-aziridine film after soaking overnight in 8M urea or 4M NaCl.

These results indicate that an extremely thin layer of HA was bound to the surfaces of the aziridine film samples in such a manner that it could not be removed by disruption of hydrophobic or static attractive forces. Such HA thin layers would be useful in preventing thrombus formation on blood contacting devices.

EXAMPLE V

CELL ADHESION FROM PLATELET RICH PLASMA

Plasma-deposited aziridine film on PET samples were examined for their resistance to cell adhesion.

Plasma-deposited aziridine film on PET samples that were made as described in Example IIA were exposed overnight at room temperature to a 0.1w% solution of 1 MDa HA buffered at pH 4.11 with a 0.03 M succinate buffer. The exposed samples were then soaked for 1 hour in phosphate buffer saline (PBS) at 37 °C and then rinsed with a large volume of reverse osmosis purified water.

The controls that were used were PET samples and plasma-deposited aziridine film samples untreated with HA. All of the samples and the controls were exposed to platelet rich plasma for 20 min. at room temperature, rinsed with PBS, fixed with 3.7% formaldehyde, stained for 90 minutes with 1% Coomassie blue, destained with 5% acetic acid and photographed under 100x magnification. Presence of cells is indicated by the color of the Coomassie blue stain that attaches on the cells.

The results obtained showed that cells adhered to the PET controls, but adhered to only two of the twelve HA-treated aziridine films prepared under a range of conditions. It was also observed that cells attached to scratches made on PET samples that had been coated with HA-treated aziridine films. These scratches were intentionally made as internal controls prior to the exposure of the films to the platelet rich plasma. These results indicate that a wide

range of HA-treated aziridine films are capable of resisting cell adhesion from platelet rich plasma.

Additionally, cells were observed not to adhere to the control aziridine film samples untreated with HA when exposed to the platelet rich plasma. This indicates that the aziridine film may absorb a layer of benign proteins such as, for example, serum albumin that inhibit platelet adhesion.

In further experiments, the plasma deposition was varied by placing the PET substrate in three different locations in the plasma reactor: upstream from, between, and downstream from the active electrodes. The plasma treated PET substrates from each of these locations were subsequently exposed to a 0.1 w% solution of 1 MDa HA as described above. It appeared that all the PET substrates that have been plasma treated and exposed to the HA solution were resistant to cell adhesion when exposed to platelet rich plasma, irrespective of the location the PET substrate was placed in the plasma reactor.

Although the invention has been described with particularity and in some detail, it will be appreciated by those skilled in this art that changes and modifications can be made therein without departing from the scope and spirit of the invention. Specifically, polysaccharides other than HA may be used to bind with the aziridine films. These polysaccharides include heparin, alginate, carboxyl methyl cellulose and dextran sulfate.

The invention is not limited by the embodiments described above which are presented as examples only but can be modified in various ways within the scope of protection defined by the appended patent claims.

Thus, while there have shown and described and pointed out fundamental novel features of the invention as applied to a preferred embodiment thereof, it will be understood that various omissions and substitutions and changes in the form and details of the processes, devices and articles illustrated, and in their operation, may be made by those skilled in the art without departing from the spirit of the invention. For example, it is expressly intended that all combinations of those elements and/or method steps which perform substantially the same function in substantially the same way to achieve the same results are within the scope of the invention. Moreover, it should be recognized that structures and/or elements and/or method steps shown and/or described in connection with any disclosed form or embodiment of the invention may be incorporated in any other disclosed or described or suggested form or embodiment as a general matter of design choice. It is the intention, therefore, to be limited only as indicated by the scope of the claims appended hereto.

References cited herein are incorporated by reference in their entirety.

CLAIMS

We claim:

1. A process of producing a coated surface on a substrate, comprising
 - a) providing a substrate; and
 - b) plasma depositing an aziridine compound onto the substrate to produce at least one aziridine-coated surface on the substrate.
2. The process of claim 1 wherein the aziridine compound has at least one other functional group selected from the group consisting of alkyl, allyl, alkoxy, alkylene, aryl, ester, ether, ethylene glycol, oligoethylene glycol, and acryl.
3. The process of claim 1 wherein the aziridine compound has a alkylene group.
4. The process of claim 3 wherein the aziridine compound has an acryl group.
5. The process of claim 4 wherein the aziridine compound has a molecular weight of 600 or less.
6. The process of claim 4 wherein the aziridine is linked to the acryl group by a linker selected from the group consisting of alkyl, alkylene, alkylene oxide, alkyl diols, and combinations thereof.
7. The process of claim 6 wherein the linker is polypropylene oxide.
8. The process of claim 6 wherein the linker is polyethylene glycol.
9. The process of claim 6 wherein the linker comprises polyethylene glycol and polypropylene oxide.

10. The process of claim 4 wherein the aziridine compound is 2-(1-aziridinyloxy)ethyl methacrylate.

11. The process of claim 1 wherein the substrate is selected from the group consisting of polyethylene terephthalate, polycarbonate, polymethacrylate, silicone, polytetrafluoroethylene, polyurethanes, polybutadienes, epoxies, polystyrenes, polybutyrates, hydroxy apatites, ceramics, glass, and metals.

12. The process of claim 1 wherein the substrate is etched with oxygen before plasma depositing the aziridine compound.

13. The process of claim 1 further comprising the step of coating the aziridine coated surface with a biopolymer.

14. The process of claim 13 wherein the biopolymer is selected from the group consisting of protein, heparin complex, polysaccharide, phosphonic acid, and nucleic acid.

15. The process of claim 14 wherein the polysaccharide is hyaluronan, alginate, or carboxymethyl cellulose.

16. The process of claim 14 wherein the protein is collagen, laminin or albumin.

17. The process of claim 14 wherein the nucleic acid is DNA, RNA or antisense material.

18. A coated substrate produced by the process of claim 1.

19. A coated substrate produced by the process of claim 10.

20. A coated substrate produced by the process of claim 13.

21. A device comprising:

(a) a substrate; and

(b) a film on said substrate, wherein said film is plasma deposited with

5 an aziridine compound.

22. The device of claim 21 wherein the aziridine compound has at least one other functional group selected from the group consisting of alkyl, allyl, alkoxy, alkylene, aryl, ester, ether, ethylene glycol, oligoethylene glycol, and acryl.

23. The device of claim 22 wherein the aziridine compound has a alkylene group.

24. The device of claim 22 wherein the aziridine compound has an acryl group.

25. The device of claim 21 wherein the aziridine compound has a molecular weight of 600 or less.

26. The device of claim 25 wherein the aziridine is linked to the acryl group by
15 a linker selected from the group consisting of alkyl, alkylene, alkylene oxide, alkyl diols and combinations there.

27. The device of claim 26 wherein the linker is polypropylene oxide.

28. The process of claim 26 wherein the linker is polyethylene glycol.

29. The process of claim 26 wherein the linker comprises polyethylene glycol
20 and polypropylene oxide.

30. The device of claim 22 wherein the aziridine compound is 2-(1-aziridinyl) ethyl methacrylate.

31. The device of claim 21 further comprising a pharmaceutical or therapeutic agent immobilized onto said film.

32. The device of claim 31 wherein said pharmaceutical or therapeutic agent is a member selected from the group consisting of anti-allergens, anti-bacterials, anti-virals, anti-fungals, anti-inflammatories, antiplatelets, antithrombotics, anesthetics, anti-proliferatives, genetic materials and mixtures thereof.

33. The device of claim 32 wherein the genetic materials are selected from the group consisting of DNA, RNA and antisense material.

34. The device of claim 21 wherein the film is covered by a biopolymer layer.

35. The device of claim 34 wherein the biopolymer is selected from the group consisting of protein, heparin complex, polysaccharide, phosphonic acid, and nucleic acid.

36. The device of claim 35 wherein the polysaccharide is hyaluronan.

37. The device of claim 34 wherein a pharmaceutical or therapeutic agent immobilized onto said biopolymer layer.

38. A method of preventing cell adhesion on a substrate comprising the application of an aziridine film on the substrate.

39. The method of claim 38, further comprising the application of a biopolymer layer on the aziridine film.

40. The method of claim 39 wherein the biopolymer is selected from the group consisting of protein, heparin complex, polysaccharide, phosphonic acid, and nucleic acid.

09
08
07
06
05
04
03
02
01
00

ABSTRACT OF THE DISCLOSURE

There are disclosed novel uses of aziridine compounds. The aziridine compounds can be formed into films by plasma deposition on a wide variety of substrates. The films prevent biofouling, impart biocompatible or antithrombotic properties, and can immobilize therapeutic and pharmaceutical agents to provide a drug delivery system.

5
037313E-041702